Columbia Laboratories, Inc. develops and commercializes pharmaceutical products that use our proprietary drug delivery technologies. We currently promote four prescription pharmaceuticals in the U.S.  We are focused predominantly on building market share of and revenues from  and      (progesterone gels), two brands of our bioadhesive natural progesterone vaginal gel used as part of an Assisted Reproductive Technology treatment for infertility and pregnancy support.  We also promote  (testosterone buccal system) for the treatment of hypogonadism in men.

We have forged partnerships to commercialize CRINONE, STRIANT and three additional products that use our Bioadhesive Delivery System (BDS) drug delivery technology in foreign markets and in U.S. markets that fall outside our strategic focus. These agreements provide us with a solid base business and enable us to remain focused on growth in our core U.S. markets.

As we work to build revenues from our current products, we are also developing new women’s healthcare products that use our BDS drug delivery technology. Our current R&D programs include PROCHIEVE 8% (progesterone gel) to reduce the risk of preterm birth in women with a short cervix at mid pregnancy and a Phase II vaginally administered lidocaine candidate for the prevention and relief of dysmenorrhea, a condition that affects over 50% of all menstruating women. To view our complete R&D pipeline, click here.

 

Company Headquarters

Columbia Laboratories, Inc.

354 Eisenhower Parkway- Plaza I - 2nd Floor

Livingston, NJ 07039

Phone: (973) 994-3999 - Fax: (973) 994-3001

Investor Contact

Melody Carey

Rx Communications Group LLC

Tel: (973) 486-8832

Fax: (866) 535-6478

Request an Investor Kit

 

Read about "RESOLVE'S" newest resource sponsored by Columbia Laboratories

Conceive® Interview with Dr. David Keefe about Crinone® 8% (progesterone gel)

Recent News

05/12/09	Data From Meta-Analysis Show Clinical Pregnancy Rate With Vaginal Progesterone is Comparable With Intramuscular Progesterone When Administered at Optimal Dosing in Infertility Patients
05/07/09	CBRX Reports Q1 2009 Financial Results
04/30/09	Columbia Laboratories to Discuss First Quarter 2009 Financial Results on May 7, 2009 Conference Call

These data are provided as a convenience for stockholders and are for informational purposes only. These data are not intended, and should not be relied upon, for trading purposes. Neither the Company nor its data providers guarantee the accuracy or completeness of any stock price or other data displayed, nor shall any such party be liable in any way to the user of the data or to any other person for any delays, inaccuracies, errors in or omission of any such data or the transmission thereof, or for any actions taken in reliance thereon or for any damages arising there from or occasioned thereby. Investors are reminded that historical and current stock price performance data are not necessarily indicative of future performance.